Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised SBB in connection with a directed share issue
Mandate

Vinge has advised SBB in connection with a directed share issue

November 24, 2021 Capital Markets and Public M&A

Vinge has advised Samhällsbyggnadsbolaget i Norden AB (”SBB”) in connection with a directed share issue, whereby SBB receives proceeds of approximately MSEK 500.


The subscription price amounts to SEK 70 per Class B common share, which corresponds to a premium of approximately 3.95 percent compared with the closing price for the Class B common share prior to the issue. The new share issue was directed to Gösta Welandson with related parties as well as Wallenstam AB.

Vinge’s team consisted of Jesper Schönbeck, Rikard Lindahl, Joel Magnusson and Anna Svensson.

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026